篮球赔率

篮球赔率 Services FAQ Contact Us 0
Home Healthcare IT Cell and Gene Therapy Market Size, Share, Demand & Growth Report by 2033
Cell and Gene Therapy Market

Cell and Gene Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Cell therapy, Gene Therapy), By Indication ( Oncology Diseases, Cardiovascular Diseases, Orthopaedic Diseases, Ophthalmology Diseases, Central Nervous System Disorders, Infectious Diseases, Others), By Delivery Method (In Vivo, Ex vivo), By End User ( Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Application (Oncology, Dermatology, Musculoskeletal, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI2269DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Cell and Gene Therapy Market Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    7. U.S.
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell therapy
          1. By Value
          2. CAR-T
            1. CAR-T By Value
            2. Autologous CAR-T
              1. Autologous CAR-T By Value
            3. Allogeneic CAR-T
              1. Allogeneic CAR-T By Value
          3. CAR-NK
            1. CAR-NK By Value
          4. B-Cell
            1. B-Cell By Value
          5. Other
            1. Other By Value
        3. Gene Therapy
          1. By Value
          2. Viral
            1. Viral By Value
            2. AAV
              1. AAV By Value
            3. Lentiviral vectors
              1. Lentiviral vectors By Value
            4. Other
              1. Other By Value
          3. Non-Viral
            1. Non-Viral By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology Diseases
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Orthopaedic Diseases
          1. By Value
        5. Ophthalmology Diseases
          1. By Value
        6. Central Nervous System Disorders
          1. By Value
        7. Infectious Diseases
          1. By Value
        8. Others
          1. By Value
      3. By Delivery Method
        1. Introduction
          1. Delivery Method By Value
        2. In Vivo
          1. By Value
        3. Ex vivo
          1. By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Academic & Research Institutes
          1. By Value
        4. Others
          1. By Value
      5. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Dermatology
          1. By Value
        4. Musculoskeletal
          1. By Value
        5. Others
          1. By Value
    8. Canada
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    7. U.K.
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell therapy
          1. By Value
          2. CAR-T
            1. CAR-T By Value
            2. Autologous CAR-T
              1. Autologous CAR-T By Value
            3. Allogeneic CAR-T
              1. Allogeneic CAR-T By Value
          3. CAR-NK
            1. CAR-NK By Value
          4. B-Cell
            1. B-Cell By Value
          5. Other
            1. Other By Value
        3. Gene Therapy
          1. By Value
          2. Viral
            1. Viral By Value
            2. AAV
              1. AAV By Value
            3. Lentiviral vectors
              1. Lentiviral vectors By Value
            4. Other
              1. Other By Value
          3. Non-Viral
            1. Non-Viral By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology Diseases
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Orthopaedic Diseases
          1. By Value
        5. Ophthalmology Diseases
          1. By Value
        6. Central Nervous System Disorders
          1. By Value
        7. Infectious Diseases
          1. By Value
        8. Others
          1. By Value
      3. By Delivery Method
        1. Introduction
          1. Delivery Method By Value
        2. In Vivo
          1. By Value
        3. Ex vivo
          1. By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Academic & Research Institutes
          1. By Value
        4. Others
          1. By Value
      5. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Dermatology
          1. By Value
        4. Musculoskeletal
          1. By Value
        5. Others
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    7. China
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell therapy
          1. By Value
          2. CAR-T
            1. CAR-T By Value
            2. Autologous CAR-T
              1. Autologous CAR-T By Value
            3. Allogeneic CAR-T
              1. Allogeneic CAR-T By Value
          3. CAR-NK
            1. CAR-NK By Value
          4. B-Cell
            1. B-Cell By Value
          5. Other
            1. Other By Value
        3. Gene Therapy
          1. By Value
          2. Viral
            1. Viral By Value
            2. AAV
              1. AAV By Value
            3. Lentiviral vectors
              1. Lentiviral vectors By Value
            4. Other
              1. Other By Value
          3. Non-Viral
            1. Non-Viral By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology Diseases
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Orthopaedic Diseases
          1. By Value
        5. Ophthalmology Diseases
          1. By Value
        6. Central Nervous System Disorders
          1. By Value
        7. Infectious Diseases
          1. By Value
        8. Others
          1. By Value
      3. By Delivery Method
        1. Introduction
          1. Delivery Method By Value
        2. In Vivo
          1. By Value
        3. Ex vivo
          1. By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Academic & Research Institutes
          1. By Value
        4. Others
          1. By Value
      5. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Dermatology
          1. By Value
        4. Musculoskeletal
          1. By Value
        5. Others
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    7. UAE
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell therapy
          1. By Value
          2. CAR-T
            1. CAR-T By Value
            2. Autologous CAR-T
              1. Autologous CAR-T By Value
            3. Allogeneic CAR-T
              1. Allogeneic CAR-T By Value
          3. CAR-NK
            1. CAR-NK By Value
          4. B-Cell
            1. B-Cell By Value
          5. Other
            1. Other By Value
        3. Gene Therapy
          1. By Value
          2. Viral
            1. Viral By Value
            2. AAV
              1. AAV By Value
            3. Lentiviral vectors
              1. Lentiviral vectors By Value
            4. Other
              1. Other By Value
          3. Non-Viral
            1. Non-Viral By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology Diseases
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Orthopaedic Diseases
          1. By Value
        5. Ophthalmology Diseases
          1. By Value
        6. Central Nervous System Disorders
          1. By Value
        7. Infectious Diseases
          1. By Value
        8. Others
          1. By Value
      3. By Delivery Method
        1. Introduction
          1. Delivery Method By Value
        2. In Vivo
          1. By Value
        3. Ex vivo
          1. By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Academic & Research Institutes
          1. By Value
        4. Others
          1. By Value
      5. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Dermatology
          1. By Value
        4. Musculoskeletal
          1. By Value
        5. Others
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell therapy
        1. By Value
        2. CAR-T
          1. CAR-T By Value
          2. Autologous CAR-T
            1. Autologous CAR-T By Value
          3. Allogeneic CAR-T
            1. Allogeneic CAR-T By Value
        3. CAR-NK
          1. CAR-NK By Value
        4. B-Cell
          1. B-Cell By Value
        5. Other
          1. Other By Value
      3. Gene Therapy
        1. By Value
        2. Viral
          1. Viral By Value
          2. AAV
            1. AAV By Value
          3. Lentiviral vectors
            1. Lentiviral vectors By Value
          4. Other
            1. Other By Value
        3. Non-Viral
          1. Non-Viral By Value
    3. By Indication
      1. Introduction
        1. Indication By Value
      2. Oncology Diseases
        1. By Value
      3. Cardiovascular Diseases
        1. By Value
      4. Orthopaedic Diseases
        1. By Value
      5. Ophthalmology Diseases
        1. By Value
      6. Central Nervous System Disorders
        1. By Value
      7. Infectious Diseases
        1. By Value
      8. Others
        1. By Value
    4. By Delivery Method
      1. Introduction
        1. Delivery Method By Value
      2. In Vivo
        1. By Value
      3. Ex vivo
        1. By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Pharmaceutical & Biotechnology Companies
        1. By Value
      3. Academic & Research Institutes
        1. By Value
      4. Others
        1. By Value
    6. By Application
      1. Introduction
        1. Application By Value
      2. Oncology
        1. By Value
      3. Dermatology
        1. By Value
      4. Musculoskeletal
        1. By Value
      5. Others
        1. By Value
    7. Brazil
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell therapy
          1. By Value
          2. CAR-T
            1. CAR-T By Value
            2. Autologous CAR-T
              1. Autologous CAR-T By Value
            3. Allogeneic CAR-T
              1. Allogeneic CAR-T By Value
          3. CAR-NK
            1. CAR-NK By Value
          4. B-Cell
            1. B-Cell By Value
          5. Other
            1. Other By Value
        3. Gene Therapy
          1. By Value
          2. Viral
            1. Viral By Value
            2. AAV
              1. AAV By Value
            3. Lentiviral vectors
              1. Lentiviral vectors By Value
            4. Other
              1. Other By Value
          3. Non-Viral
            1. Non-Viral By Value
      2. By Indication
        1. Introduction
          1. Indication By Value
        2. Oncology Diseases
          1. By Value
        3. Cardiovascular Diseases
          1. By Value
        4. Orthopaedic Diseases
          1. By Value
        5. Ophthalmology Diseases
          1. By Value
        6. Central Nervous System Disorders
          1. By Value
        7. Infectious Diseases
          1. By Value
        8. Others
          1. By Value
      3. By Delivery Method
        1. Introduction
          1. Delivery Method By Value
        2. In Vivo
          1. By Value
        3. Ex vivo
          1. By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Pharmaceutical & Biotechnology Companies
          1. By Value
        3. Academic & Research Institutes
          1. By Value
        4. Others
          1. By Value
      5. By Application
        1. Introduction
          1. Application By Value
        2. Oncology
          1. By Value
        3. Dermatology
          1. By Value
        4. Musculoskeletal
          1. By Value
        5. Others
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Cell and Gene Therapy Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Thermo Fisher Scientific
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Merck KGaA
    3. Charles River Laboratories
    4. Lonza
    5. Catalent
    6. WuXi AppTec
    7. Takara Bio Inc.
    8. Nikon Corporation
    9. FUJIFILM Holdings Corporation
    10. Hoffmann-La Roche Ltd.
    11. Oxford Biomedica plc
    12. Amgen Inc.
    13. Novartis AG
    14. Pfizer Inc.
    15. Biogen Inc
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Cell and Gene Therapy Manufacturing QC Market Size The global cell and gene therapy manufacturing QC market size was valued at USD 2.24 billion in 2024 and is projected to grow from USD 2.82 billion in 2025 to USD 17.55 billion by 2033, exhibiting a
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

篮球赔率
漏 Copyright . All rights Reserved.